ENGLEWOOD, Colo., Jan. 25, 2016 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial in
details for a scheduled 2016 Corporate Update on Thursday, January 28, 4:30pm EST. Participants are invited to dial in
using the instructions as follows:
Investor call information:
U.S./Canada toll-free number:
877-419-6593
International toll number: 719-325-4908
Participant Passcode: 5483251
Questions can be emailed in advance to April Ramirez, aramirez@ampiopharma.com.
Access will be provided through an operator for Q&A,
participants will be instructed on how to submit questions at the
time of the call.
About Ampio Pharmaceuticals:
Ampio Pharmaceuticals, Inc. is a clinical trial stage
biopharmaceutical company primarily focused on the development of
therapies to treat prevalent inflammatory conditions for which
there are limited treatment options. We are developing compounds
that decrease inflammation by (i) inhibiting specific
pro-inflammatory compounds by affecting specific pathways at the
protein expression and at the transcription level; (ii) activating
specific phosphatase or depletion of the available phosphate needed
for the inflammation process; and (iii) decreasing vascular
permeability.
Forward Looking Statements:
Ampio's statements in this
press release that are not historical fact and that relate to
future plans or events are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by use of words such
as "believe," "expect," "plan," "anticipate," and similar
expressions. These forward-looking statements include risks
associated with clinical trials, expected results, regulatory
approvals, and changes in business conditions and similar events.
The risks and uncertainties involved include those detailed from
time to time in Ampio's filings with the Securities and Exchange
Commission, including without limitation, under Ampio's Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:
Gregory A. Gould
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6513
Email: ggould@ampiopharma.com
Logo - http://photos.prnewswire.com/prn/20120516/MM09116LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ampio-announces-2016-corporate-update-on-thursday-january-28-430pm-est-300208864.html
SOURCE Ampio Pharmaceuticals, Inc.